Fusion Antibodies raises $2.5M for antibody tech
Fusion Antibodies, an Irish biotech focused on — you guessed it — antibody tools and drugs, raised $2.5 million (£1.2 million) to push unidentified drug candidates through animal testing. Participants in the round included Crescent Capital, Viridian Growth Fund, QUBIS, University Challenge Fund and Invest Northern Ireland. The company also said it received a $820,000 (£400,000) research grant through the Invest Northern Ireland START program.
More details here.
Next Story: Biotech financing: Will ImaRx break the IPO slump?
Previous Story: Active Athlete Media and the emergence of niche ad networks
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.
VB Writers
Ben PopperEast Coast Editor
Dean TakahashiLead Writer, GamesBeat
Devindra HardawarNational Editor, MobileBeat Lead
Dylan TweneyExecutive Editor
ShoeEditor-in-Chief, GamesBeat
Heather KellySenior Editor
Jennifer Van GroveWriter
Jolie O'DellWriter
Matt MarshallFounder & Editor-in-Chief
Meghan KellyWriter
Sarah MitroffEditorial Assistant
Sean LudwigWriter
Sebastian HaleyReviews Editor, GamesBeat
Tom CheredarWriter
Ciara ByrneContributor
Julia PlevinContributor
Lindsey ComptonContributor
